A pivotal noninferiority study of ViaLase's noninvasive laser glaucoma treatment, femtosecond laser image-guided high-precision trabeculotomy (FLigHT) vs selective laser trabeculoplasty, is fully enrolled, according to a company news release.

"ViaLase believes our technology will give doctors the opportunity to intervene earlier in the treatment paradigm with a potentially safe and effective noninvasive procedure," said ViaLase Chief Medical Officer Richard Lewis, MD.

The ViaLase laser combines a femtosecond laser and micron-level, high-definition image guidance, allowing the user to noninvasively create a conduit between Schlemm's canal and the anterior chamber, according to the maker. According to the news release, ViaLase believes that the technology addresses an unmet need for a "noninvasive procedure for patients who would benefit from a nonpharmacological, nonsurgical procedure but whose therapeutic goals do not justify the risks of a surgically invasive procedure such as minimally invasive glaucoma surgery or traditional filtration surgery."